# Quaker Partners

> Quaker Partners is a VC fund backing Health Care and Biotechnology. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Philadelphia, United States
- Total investments: 15
- Last investment: May 2019
- Lead investor: 13%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/quaker-partners
- X (Twitter): https://twitter.com/QuakerPartners
- Website: http://www.quakerpartners.com

Quaker Partners is a healthcare investment firm focused on companies based on the U.S. East Coast.

## Contacts

5 contacts available for Quaker Partners. Shizune tracks 2 team members at Quaker Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/quaker-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $7M–$39M |
| Series C | $20M–$35M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 40% |
| Biotechnology | 6 | 40% |
| Medical Device | 4 | 27% |
| Therapeutics | 3 | 20% |
| Pharmaceutical | 3 | 20% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 20% |
| Series C | 3 | 20% |
| Funding Round | 3 | 20% |
| Series A | 2 | 13% |
| Seed | 1 | 7% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 53% |
| New Zealand | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| P. Sherrill Neff | Partner | 3 | https://shizune.co/investors/profile/p-sherrill-neff |
| Brian Schwenk | CFO | 0 | https://shizune.co/investors/profile/brian-schwenk |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Intact Vascular | Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheralartery disease. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products.The company was founded in 2011 and is located at Wayne, PA, USA. | $25M | Series D | May 30, 2019 |  |
| Vesper Medical | Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them. The company's core technology, the Vesper DUO Venous Stent System, is purpose-built for venous stenting, with an unmatched combination of strength and flexibility designed to meet themultiple anatomical challenges presented by vein mechanics.Vesper Medical is advancing the treatment of deep venous disease by creating a highly differentiated, purpose-built venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins. It also develops minimally- invasive peripheral vascular products. Vesper Medical was founded in 2016 and is headquartered in Wayne, PA, USA. | $37M |  | May 29, 2019 |  |
| Vital | Keep patients more informed and engaged in the emergency room, hospital, and beyond. Vital’s AI-powered patient experience solutions give patients control, clarity, and predictability when they need it most. | $5.2M | Seed | Apr 24, 2019 |  |
| Vesper Medical | Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them. The company's core technology, the Vesper DUO Venous Stent System, is purpose-built for venous stenting, with an unmatched combination of strength and flexibility designed to meet themultiple anatomical challenges presented by vein mechanics.Vesper Medical is advancing the treatment of deep venous disease by creating a highly differentiated, purpose-built venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins. It also develops minimally- invasive peripheral vascular products. Vesper Medical was founded in 2016 and is headquartered in Wayne, PA, USA. | $10.5M | Series A | May 12, 2018 |  |
| Intact Vascular | Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheralartery disease. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products.The company was founded in 2011 and is located at Wayne, PA, USA. | $20M | Series C | Apr 16, 2018 |  |
| TELA Bio | TELA Bio is a life science company that specializes in soft tissue reconstruction. The company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair. | $25M |  | Oct 30, 2017 |  |
| Intact Vascular | Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheralartery disease. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products.The company was founded in 2011 and is located at Wayne, PA, USA. | $7.1M | Series B | Jan 03, 2017 |  |
| Intact Vascular | Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheralartery disease. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products.The company was founded in 2011 and is located at Wayne, PA, USA. | $38.9M | Series B | May 14, 2015 |  |
| Rapid Micro Biosystems | Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $25M | Series C | Apr 29, 2015 |  |
| Tarsa Therapeutics | Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction. | $7M | Series B | May 29, 2014 |  |

10 of 15 investments shown.

## Co-investors
- [H.I.G. BioHealth Partners](https://shizune.co/investors/profile/h-i-g-biohealth-partners) — VC Fund, 4 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 4 deals together
- [Longitude Capital](https://shizune.co/investors/profile/longitude-capital) — VC Fund, 3 deals together
- [TVM Capital](https://shizune.co/investors/profile/tvm-capital) — VC Fund, 3 deals together
- [Vensana Capital](https://shizune.co/investors/profile/vensana-capital) — VC Fund, 2 deals together
- [Baxter Ventures](https://shizune.co/investors/profile/baxter-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Icehouse Ventures](https://shizune.co/investors/profile/icehouse-ventures) — VC Fund
- [Enterprise Angels](https://shizune.co/investors/profile/enterprise-angels) — VC Fund
- [K1W1](https://shizune.co/investors/profile/k1w1) — VC Fund

## Featured in investor lists
- [Health Care Investors in New Zealand](https://shizune.co/investors/health-care-investors-new-zealand)
- [Artificial intelligence VC Funds in New Zealand](https://shizune.co/investors/artificial-intelligence-vc-funds-new-zealand)
- [Health Care VC Funds in New Zealand](https://shizune.co/investors/health-care-vc-funds-new-zealand)

## FAQ

### What does Quaker Partners invest in?

Quaker Partners invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series C stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Quaker Partners's check size?

Quaker Partners typically joins rounds of $7M–$39M at Series B and $20M–$35M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Quaker Partners participates in.

### How do I contact Quaker Partners?

Public channels for Quaker Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Quaker Partners?

The team at Quaker Partners includes P. Sherrill Neff (Partner) and Brian Schwenk (CFO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co